[1] Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and meta analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2004, 89(8): 3668-3676.
[2] Creutzig H. High or low dose radioiodine ablation of thyroid remnants?[J]. Eur J Nucl Med, 1987, 12(10): 500-502.
[3] Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer[J]. J Nucl Med, 1991, 32(2): 252-254.
[4] Bal C, Padhy AK, Jana S, et al. Prospective randomized clinical trial to evaluate the optimal dose of 131I for remnant ablation in patients with differentiated thyroid carcinoma[J]. Cancer, 1996, 77(12): 2574-2580.
[5]

Mäenpää HO, Heikkonen J, Vaalavirta L, et al. Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study[J/OL]. PLoS One, 2008, 3(4): e1885[2014-03-01]. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001885.
[6] Kukulska A, Krajewska J, Gawkowska-Suwińska M, et al. Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma(DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi[J]. Thyroid Res, 2010, 3(1): 9.
[7] Fallahi B, Beiki D, Takavar A, et al. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial[J]. Nucl Med Commun, 2012, 33(3): 275-282.
[8] Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer[J]. N Engl J Med, 2012, 366(18): 1663-1673.
[9] Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer[J]. N Engl J Med, 2012, 366(18): 1674-1685.
[10] Caglar M, Bozkurt FM, Akca CK, et al. Comparison of 800 and 3700MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer[J]. Nucl Med Commun, 2012, 33(3): 268-274.
[11] Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal[J]. J Clin Endocrinol Metab, 2002, 87(9): 4063-4068.
[12] Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30mCi after recombinant human thyrotropin stimulation in thyroid cancer. effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation[J]. J Clin Endocrinol Metab, 2003, 88(9): 4110-4115.
[13] Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study[J]. J Clin Endocrinol Metab, 2006, 91(3): 926-932.
[14] Verkooijen RB, Verburg FA, van Isselt JW, et al. The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and fixed-dose strategies[J]. Eur J Endocrinol, 2008, 159(3): 301-307.
[15] Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2008, 93(2): 504-515.
[16] Rosário PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity[J]. J Nucl Med, 2008, 49(11): 1776-1782.
[17] Esfahani AF, Fallahi B, Olamaie R, et al. Semi-quantitative assessment of salivary gland function in patients with differentiated thyroid carcinoma after radioiodine-131 treatment[J]. Hell J Nucl Med, 2004, 7(3): 206-209.
[18] Borget I, Remy H, Chevalier J, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen[J]. Eur J Nucl Med Mol Imaging, 2008, 35(8): 1457-1463.